Angiotensin receptor-neprilysin inhibitors are heart failure drugs that combine angiotensin II receptor blockade with neprilysin inhibition. In Intro to Pharmacology, they show how one drug can lower blood pressure and improve cardiac output at the same time.
Angiotensin receptor-neprilysin inhibitors, or ARNIs, are a drug class used mainly in heart failure, especially heart failure with reduced ejection fraction. The best-known example is sacubitril/valsartan, which pairs two actions in one medication: it blocks the angiotensin II receptor and inhibits neprilysin.
That dual action matters because heart failure is not just a weak pump problem. The body tries to compensate by turning on the renin-angiotensin-aldosterone system, which raises vasoconstriction, sodium retention, and fluid buildup. Blocking angiotensin II at its receptor helps turn down that harmful compensation, so the heart does not face as much pressure and volume stress.
The neprilysin side is the part students often miss. Neprilysin is an enzyme that breaks down natriuretic peptides such as ANP and BNP. Those peptides normally push the body toward vasodilation, natriuresis, and diuresis, which means they help get rid of salt and water. If you inhibit neprilysin, those helpful peptides stay around longer, so the drug supports the body’s own unloading pathway.
That is why ARNIs are not just another blood pressure medication. They shift the balance away from vasoconstriction and fluid retention and toward vasodilation and fluid loss, which can improve symptoms like shortness of breath and swelling. In pharmacology, that makes them a good example of how a combination drug can target two sides of the same disease process.
The common clinical example is sacubitril/valsartan, and it is often discussed alongside ACE inhibitors and ARBs. One big safety point is the angioedema risk, especially if a patient has had angioedema with ACE inhibitors. You also watch for hypotension, hyperkalemia, and renal impairment, because the same mechanisms that help the heart can also lower blood pressure and affect kidney function.
ARNIs matter in Intro to Pharmacology because they connect receptor pharmacology, enzyme inhibition, and cardiovascular physiology in one case. If you can explain why sacubitril/valsartan helps heart failure, you are showing that you understand how drugs change body signaling, not just how to memorize a name.
This term also helps you compare drug classes that students often group together too quickly. ACE inhibitors, ARBs, beta-blockers, aldosterone antagonists, and ARNIs all treat heart failure, but they do it through different pathways. ARNIs stand out because they increase beneficial natriuretic peptide activity while also blocking angiotensin II signaling.
That makes the term useful for side-effect reasoning too. Hypotension, hyperkalemia, renal problems, and angioedema are not random facts, they follow from how the drug changes blood vessels, fluid balance, and hormone pathways. When a quiz gives you a patient scenario, this is the sort of mechanism you use to predict what might happen next.
It also shows why combination therapy exists in pharmacology. A single pathway is often not enough in heart failure, so clinicians use more than one mechanism to reduce workload on the heart and improve outcomes.
Keep studying Intro to Pharmacology Unit 7
Visual cheatsheet
view galleryNeprilysin
Neprilysin is the enzyme ARNIs block on one side of the combination. In heart failure, inhibiting it keeps ANP and BNP active longer, which promotes natriuresis and vasodilation. If you understand neprilysin alone, the ARNI mechanism makes more sense, because the drug is basically preserving the body’s own pressure-relief signals.
Angiotensin II
Angiotensin II is the target of the receptor-blocking part of an ARNI. It normally causes vasoconstriction and supports aldosterone release, which increases sodium and water retention. ARNIs reduce those effects by blocking the receptor, so they counter one of the main hormone systems that worsens heart failure.
Heart Failure
Heart failure is the main condition ARNIs are used for. The drug makes sense in this context because heart failure triggers compensatory systems that raise fluid retention and vessel constriction. ARNIs help shift the body away from that stressful pattern, so they fit directly into treatment plans for reduced ejection fraction.
Contraindicated Medications
ARNIs are often discussed with contraindications because of the angioedema risk and the need to avoid unsafe combinations. If a patient has a history of ACE inhibitor-related angioedema, that is a red flag. This connection helps you practice medication safety, not just mechanism recall.
A quiz question or case study may give you a patient with heart failure symptoms and ask which drug class combines an ARB with neprilysin inhibition. Your job is to recognize sacubitril/valsartan, connect it to vasodilation and natriuresis, and predict the main monitoring concerns. If the case mentions low blood pressure, high potassium, kidney issues, or prior angioedema with an ACE inhibitor, those details point you toward the safety profile of an ARNI. You may also be asked to compare it with an ACE inhibitor or ARB, so be ready to explain that ARNIs do more than block angiotensin signaling, they also preserve natriuretic peptides. In short-answer work, the strongest response ties the drug’s mechanism to heart failure symptoms and to the reason it improves outcomes.
ARNIs and ACE inhibitors both reduce harmful angiotensin effects, so they are easy to mix up. The difference is that ARNIs also inhibit neprilysin, which raises natriuretic peptides and adds a second benefit. ACE inhibitors block conversion of angiotensin I to angiotensin II, while ARNIs block the angiotensin II receptor and preserve ANP and BNP activity.
Angiotensin receptor-neprilysin inhibitors are heart failure drugs that combine angiotensin II receptor blockade with neprilysin inhibition.
The ARB part lowers angiotensin II effects, which reduces vasoconstriction, sodium retention, and strain on the heart.
The neprilysin inhibitor part keeps natriuretic peptides active longer, so the body can vasodilate and excrete more salt and water.
Sacubitril/valsartan is the classic example, and it is especially used in heart failure with reduced ejection fraction.
Watch for hypotension, hyperkalemia, renal impairment, and angioedema risk when this drug class comes up in case questions.
Angiotensin receptor-neprilysin inhibitors are a class of heart failure medications that block angiotensin II receptors and inhibit neprilysin at the same time. That combination lowers harmful vasoconstriction while preserving natriuretic peptides that help the body get rid of excess fluid. In pharmacology class, they are a good example of a dual-mechanism drug.
Sacubitril/valsartan is the main example you will see. Sacubitril inhibits neprilysin, while valsartan blocks the angiotensin II receptor. The pairing makes it useful for heart failure because it both reduces fluid overload and eases pressure on the heart.
An ARB only blocks the angiotensin II receptor. An ARNI does that too, but it also inhibits neprilysin, which increases beneficial natriuretic peptides like ANP and BNP. That extra mechanism is why ARNIs are discussed as more than just another blood pressure drug.
They can cause hypotension, hyperkalemia, and kidney problems, so patients need monitoring. They are also avoided in people with a history of angioedema related to ACE inhibitors because the risk can be dangerous. That safety detail often shows up in medication case questions.